← back to search

Mengzhong Liu

State Key Laboratory of Oncology in South China · CN
Area of research
Surgery · Otorhinolaryngology
Research interest
Research interests include Esophageal Cancer Research and Treatment, Head and Neck Cancer Studies, Colorectal and Anal Carcinomas, and Hepatocellular Carcinoma Treatment and Prognosis.
h-index
27
citations
4,110
works
120
NIH funding
primary concept
Medicine
email

Recent publications

Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
Nature Communications 2024cited by 24position: middledoi
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
The Lancet Oncology 2023cited by 95position: middledoi
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
EClinicalMedicine 2023cited by 46position: middledoi
Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010
Journal of Thoracic and Cardiovascular Surgery 2022cited by 25position: middledoi
Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
JAMA Surgery 2021cited by 339position: middledoi
TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
Cell Death and Disease 2021cited by 64position: middledoi
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
Nature Communications 2021cited by 54position: middledoi
Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Annals of Surgery 2021cited by 48position: middledoi
Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)
Annals of Translational Medicine 2021cited by 40position: middledoi
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010
European Journal of Cancer 2020cited by 104position: middledoi
Linc-RA1 inhibits autophagy and promotes radioresistance by preventing H2Bub1/USP44 combination in glioma cells
Cell Death and Disease 2020cited by 54position: middledoi
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Frontiers in Oncology 2019cited by 84position: middledoi
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
Journal of Clinical Oncology 2018cited by 964position: middledoi
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
Medicine 2018cited by 105position: middledoi
Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer
Annals of Surgery 2018cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Mian Xi · Union Hospital6 papers (2018–2024)Qiaoqiao Li · Jiangnan University5 papers (2020–2024)Shiliang Liu · Sun Yat-sen University5 papers (2020–2024)Yonghong Hu · State Key Laboratory of Oncology in South China5 papers (2020–2024)Hong Yang · Kunming Medical University5 papers (2018–2024)Lei Zhao · Sichuan Agricultural University4 papers (2020–2023)Yujia Zhu · Zhejiang Chinese Medical University3 papers (2021–2024)Baoqing Chen · University of Colorado Denver3 papers (2023–2024)Hui Liu · Sun Yat-sen University3 papers (2020–2021)Jianhua Fu · Jiangsu University3 papers (2020–2023)Li Zhang · Sun Yat-sen University3 papers (2018–2023)Jiaqing Xiang · Fudan University Shanghai Cancer Center2 papers (2020–2021)Yingxin Lv · Sun Yat-sen University2 papers (2023–2023)Wentao Fang · Henan Cancer Hospital2 papers (2020–2021)Yawei Yuan · Ruijin Hospital2 papers (2018–2020)Jie Lin · Kunming Institute of Botany2 papers (2018–2019)Muhammad Khan · Anhui Medical University2 papers (2018–2019)Rong Li · University of Alabama at Birmingham2 papers (2018–2019)Yuping Chen · Nanjing University of Finance and Economics2 papers (2020–2021)Zhentao Yu · Southwest University of Science and Technology2 papers (2020–2021)